Key facts
- Notable investors include Changxing Fund, Changchun Financial Holding Group, Changchun Huize Investment, Jilin Province Private Equity, Jilin Province Technology Investment Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Jianglin Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Jianglin Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jianglin Bio
Manufacturer of innovative small molecule therapeutic compounds designed to address complex diseases, including malignant tumours and immune-inflammatory disorders. The company offers epigenetics-guided drug discovery platforms, targeted molecular candidates, and early clinical development capabilities, enabling patients with challenging cancers and immune conditions to access advanced treatment options grounded in genetic and transcriptional science.
- Sector
- Healthcare
- HQ
- Changchun, China
- Founded
- 2019
- Ownership
- Privately Held (backing)
Jianglin Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jianglin Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jianglin Bio in its N-PORT filings yet. We sweep new filings monthly.